PAVmed (PAVM) Projected to Post Quarterly Earnings on Monday

PAVmed (NASDAQ:PAVM) is anticipated to post its Q4 2025 results before the market opens on Monday, March 30th. Analysts expect PAVmed to post earnings of ($4.50) per share for the quarter. Individuals can check the company’s upcoming Q4 2025 earning summary page for the latest details on the call scheduled for Monday, March 30, 2026 at 8:30 AM ET.

PAVmed Stock Up 1.8%

PAVmed stock opened at $9.86 on Monday. PAVmed has a twelve month low of $6.00 and a twelve month high of $28.44. The company has a market capitalization of $9.66 million, a P/E ratio of -0.58 and a beta of 0.90. The stock’s 50 day moving average is $9.70 and its 200 day moving average is $10.82.

Institutional Trading of PAVmed

An institutional investor recently raised its position in PAVmed stock. Jane Street Group LLC raised its holdings in shares of PAVmed Inc. (NASDAQ:PAVM) by 392.9% during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 52,676 shares of the company’s stock after purchasing an additional 41,990 shares during the period. Jane Street Group LLC owned approximately 0.31% of PAVmed worth $32,000 at the end of the most recent quarter. Institutional investors own 19.93% of the company’s stock.

Analysts Set New Price Targets

Several research firms have commented on PAVM. Ascendiant Capital Markets dropped their target price on PAVmed from $600.00 to $510.00 and set a “buy” rating on the stock in a report on Wednesday, December 10th. Weiss Ratings restated a “sell (d)” rating on shares of PAVmed in a report on Thursday, January 22nd. Wall Street Zen raised PAVmed to a “sell” rating in a research report on Saturday, February 14th. Finally, Zacks Research cut shares of PAVmed from a “strong-buy” rating to a “hold” rating in a research note on Monday, November 24th. One equities research analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Hold” and an average target price of $510.00.

PAVmed Company Profile

PAVmed Inc is a clinical-stage medical technology company focused on acquiring, developing and commercializing innovative medical devices aimed primarily at gastrointestinal endoscopy and related therapeutic areas. Its portfolio includes FDA-cleared products such as EsoFLIP® Distensibility System for the treatment of esophageal strictures and MUSE™ (Medigus Ultrasonic Surgical Endostapler) for endoscopic fundoplication in gastroesophageal reflux disease (GERD). In addition to its gastrointestinal franchise, PAVmed is advancing early-stage programs targeting indications in oncology, urology and dermatology.

Founded in 2012, PAVmed has built its pipeline through internal research and development as well as strategic collaborations and acquisitions.